ESTRO consensus recommendations on total skin electron beam technique - Endorsed by ILROG☆ Authors: Christos Moustakis, Isak Hannes Wahlstedt, Kalliopi-Pola Platoni, Tze Yee Lim, María Aurora Vicedo González, Trinitat García Hernández, Mario Levis, Gabriele Simontacchi, Belinda A. Campbell, Stefanie Corradini, Stephen Morris, George Patatoukas, Youlia Kirova, Bouthaina Dabaja, Hans Theodor Eich, Sabbah I. Hammoury, Andrea Baehr, Livia Marrazzo, Laila König, Mohamed A. Schumann, Lena Specht, Richard Cowan, Khaled Elsayad Published: 2026 ABSTRACT Background and purposeTotal skin electron beam therapy (TSEBT) is an established radiation treatment modality for the management of cutaneous T-cell lymphoma (CTCL). In recent years, there has been an increasing interest in dose de-escalation strategies aimed at lowering treatment-induced side effects whilst maintaining efficacy. This evolution in clinical practice has highlighted the need for consistent technical standards to ensure treatment quality and comparability across medical institutions. A unified set of recommendations for TSEBT in the modern era was sought by the European Society for Radiotherapy and Oncology (ESTRO) Guidelines Sub-Group on Physics, including physical requirements, with the aim of harmonizing clinical practice, promoting homogeneity for clinical trials, and facilitating wider adoption of the technique.Material and methodsThe ESTRO Guidelines Committee developed these recommendations using a Delphi consensus methodology. An expert panel consisting of radiation oncologists and medical physicists with specific expertise in the radiation treatment of primary cutaneous lymphoma was convened. Panel members completed a 14-question survey focusing on key technical aspects of TSEBT.ResultsConsensus was achieved on the principal physical and technical components of TSEBT delivery, including prescribed dose levels, field dimensions, treatment techniques, and QA requirements. Areas of agreement reflect current best practices and address sources of variability that may impact treatment reproducibility.ConclusionsESTRO recommendations provide a standardised framework for the delivery of TSEBT in the management of CTCL, supporting safe implementation and consistency across medical institutions in the context of reduced-dose treatment approaches. Introduction Total skin electron beam therapy (TSEBT) is an established radiation therapy modality used in the management of cutaneous T-cell lymphomas (CTCL) and is primarily used in the skin-directed treatment of mycosis fungoides (MF). TSEBT achieves high overall response rates, approaching 100%, with an acceptable, dose-dependent side-effect profile [1], [2], [3], [4], [5], [6], [7]. To minimize the treatment-related side effects of conventional TSEBT doses, low-dose TSEBT has gained increased interest as a skin-directed therapy for patients with MF [8], [9], [10], and has been widely adopted by CTCL specialists in clinical practice. More recently, the value of adjunctive therapies to extend the durability of treatment response from low-dose TSEBT, has become a topical research question [11]. Despite its proven efficacy, the availability and accessibility of TSEBT remain limited [12], resulting in lower-than-expected utilization rates [13]. Furthermore, the lack of international consensus on the optimal therapeutic treatment pathways creates uncertainty for the multidisciplinary teams responsible for treatment decisions and contributes to heterogeneity in clinical practices globally [9], [14], [15], [16]. These challenges to equitable and consistent care are further compounded by the technical complexity of TSEBT and the diversity of delivery techniques that have evolved across institutions. Published in 2002, consensus guidelines of the European Organisation for Research and Treatment of Cancer (EORTC) addressed the clinical indications and technical recommendations for conventional-dose TSEBT [17]. However, as TSEBT techniques have evolved over time, substantial heterogeneity in treatment delivery has emerged, leading to variations in clinical care and complicating the interpretation and application of published clinical data. More recent EORTC radiotherapy guidelines now recommend 8–12 Gy for low-dose TSEBT, although higher doses may still have utility and are favoured in the setting of allogeneic stem cell transplantation for maximal debulking of skin prior to transplant [8]. Given these recent changes in practice, the ESTRO Guidelines Committee sought to establish clear and practical recommendations for the delivery of low-dose TSEBT in patients with MF. The aims of these recommendations are to improve consistency in clinical practice, promote homogeneity in clinical research, and facilitate wider and safer implementation of TSEBT across radiation oncology centres. Particular emphasis was placed on providing clear explanations of the underlying physical principles and quality assurance (QA) requirements, which are essential for the safe implementation and reproducible delivery of TSEBT. These consensus recommendations cover key aspects of TSEBT delivery, including prescription dose levels, treatment techniques, and the management and shielding of organs at risk. The recommendations are based on the collective experience and established practices of ESTRO members with expertise in the delivery of TSEBT. Materials and methods Between October and November 2024, a scientific panel consisting of seven experts in radiation oncology (five physicians and two physicists) with specific expertise in primary cutaneous lymphoma developed a dedicated questionnaire. From December 2024 to May 2025, the questionnaire was distributed in three rounds to 16 radiation oncology experts affiliated with ESTRO (Table 1), following the Delphi methodology (Fig. 1). This carefully designed tool comprised 14 multiple-choice questions addressing key technical and quality-related issues in the field (Table 2). The survey was administered electronically. The expert panel included nine male and seven female participants, all working in academic institutions. Participants reported a median of 20 patients treated per year with TSEBT (range: 10–75). In line with previously published data [18], the six-field dual-angle Stanford technique was the most commonly adopted approach, reported by 78% of participating institutions.Table 1Respondent and institution characteristics.CharacteristicN (%)Specialties of the writing panel members16 (100)Medical physics7 (44)Radiation oncology5 (31)Clinical oncology4 (25)Number of patients treated per year (median, range)20 (10–75) Radiation regimens28 (100)4 Gy in 2–4 fractions2 (12)8 Gy in 2 fractions3 (19)10 Gy in 10 fractions3 (19)12 Gy in 6 fractions4 (25)12 Gy in 8 fractions8 (50)12 Gy in 12 fractions2 (12)10 Gy in 5 fractions2 (12)15 Gy in 12 fractions2 (12)Higher doses (24–30 Gy) over 5–8 weeks2 (12) TSEBT Techniques18 (100)Dual-field Stanford technique14 (78)Single-field Stanford technique1 (5.5)Rotational total skin electron beam therapy2 (11)Photons (i.e. IMRT, Tomotherapy)1 (5.5)N: number of experts, TSEBT: total skin electron beam therapy, IMRT: Intensity-Modulated Radiation Therapy.Fig. 1Study flow diagram of the 3 rounds of the Delphi consensus.Fig. 1Table 2Summary of Delphi consensus recommendations for total skin electron beam therapy.DomainTopicConsensus recommendationRoundAgreement (%)TechniqueBeam modality and energyElectrons should be used for total skin irradiation, and the electron energies must be specified based on the depth-dose characteristics.Round 1Round 260100TechniqueDaily and cumulative radiation doseThe daily radiation dose to each treated area should be determined according to the clinical situation, with a lifetime cumulative dose to the whole skin not exceeding 60 Gy, a local cumulative dose not exceeding 100 Gy, and the dose per fraction should be taken into account.Round 1Round 27594TechniquePatient positioningTSEBT requires patients to be in a standing position.Round 1Round 26981TechniqueField arrangementA dual-angle technique is generally preferred, although a single-angle technique can be used.Round 181TechniqueFraction deliveryDepending on the clinical condition of the patient and the resources of the radiotherapy facility, all fields should be applied within one scheduled fraction. Alternatively, all fields may be applied over two days.Round 1Round 27588TechniqueOrgan protectionProtecting the nails and eyes is essential to avoid side effects; however, if tissues adjacent to the nails or eyelids are involved or in case of subungual disease, nails and eyelids may be irradiated with careful attention to the risk of local side effects.Round 194TechniqueShielding optionsDuring TSEBT, avoid shielding the face and scalp to minimize the risk of local relapses. However, after discussing the associated risks, shared decision-making to shield face or scalp may be an option for patients who prefer to avoid hair loss in order to maintain their quality of life.Round 1Round 2Round 3446394TechniqueSpecial anatomical considerationsFor women with pendulous breasts, an irradiation bra can be used to enable sufficient dose distribution in the inframammary fold.Round 1Round 26781TechniqueAdministration of local patches or boostBased on clinical circumstances, local supplementary fields to the underdosed areas (e.g., anal folds, soles, inframammary folds) or focal radiotherapy for tumorous or residual lesions may be administered using orthovoltage, electrons, photons (e.g., IMRT, VMAT, or tomotherapy), or brachytherapy.Round 194Physics / QABeam modifiersA scatterer-degrader plate or a specialised flattening filter should be used during TSEBT to achieve the desired dose uniformity and skin dose.Round 194Physics / QATreatment distanceThe optimal treatment distance between the gantry and the patient should be assessed through measurements.Round 1100Physics / QASurface doseThe required surface dose should range from 80% to 120% of the prescribed dose.Round 1Round 26394Physics / QAIn vivo dosimetryDosimetric measurements for quality control (in vivo dosimetry) should be performed at least for a set of patients when starting the TSEBT program.Round 1100Physics / QAQuality assuranceQuality-assurance procedures, including regular equipment calibration, patient-specific dosimetric verification, and end-to-end testing or auditor certification, are recommended.Round 1100QA: quality assurance, TSEBT: total skin electron beam technique. Table 1Respondent and institution characteristics.CharacteristicN (%)Specialties of the writing panel members16 (100)Medical physics7 (44)Radiation oncology5 (31)Clinical oncology4 (25)Number of patients treated per year (median, range)20 (10–75) Radiation regimens28 (100)4 Gy in 2–4 fractions2 (12)8 Gy in 2 fractions3 (19)10 Gy in 10 fractions3 (19)12 Gy in 6 fractions4 (25)12 Gy in 8 fractions8 (50)12 Gy in 12 fractions2 (12)10 Gy in 5 fractions2 (12)15 Gy in 12 fractions2 (12)Higher doses (24–30 Gy) over 5–8 weeks2 (12) TSEBT Techniques18 (100)Dual-field Stanford technique14 (78)Single-field Stanford technique1 (5.5)Rotational total skin electron beam therapy2 (11)Photons (i.e. IMRT, Tomotherapy)1 (5.5)N: number of experts, TSEBT: total skin electron beam therapy, IMRT: Intensity-Modulated Radiation Therapy. Respondent and institution characteristics. N: number of experts, TSEBT: total skin electron beam therapy, IMRT: Intensity-Modulated Radiation Therapy. Study flow diagram of the 3 rounds of the Delphi consensus. Table 2Summary of Delphi consensus recommendations for total skin electron beam therapy.DomainTopicConsensus recommendationRoundAgreement (%)TechniqueBeam modality and energyElectrons should be used for total skin irradiation, and the electron energies must be specified based on the depth-dose characteristics.Round 1Round 260100TechniqueDaily and cumulative radiation doseThe daily radiation dose to each treated area should be determined according to the clinical situation, with a lifetime cumulative dose to the whole skin not exceeding 60 Gy, a local cumulative dose not exceeding 100 Gy, and the dose per fraction should be taken into account.Round 1Round 27594TechniquePatient positioningTSEBT requires patients to be in a standing position.Round 1Round 26981TechniqueField arrangementA dual-angle technique is generally preferred, although a single-angle technique can be used.Round 181TechniqueFraction deliveryDepending on the clinical condition of the patient and the resources of the radiotherapy facility, all fields should be applied within one scheduled fraction. Alternatively, all fields may be applied over two days.Round 1Round 27588TechniqueOrgan protectionProtecting the nails and eyes is essential to avoid side effects; however, if tissues adjacent to the nails or eyelids are involved or in case of subungual disease, nails and eyelids may be irradiated with careful attention to the risk of local side effects.Round 194TechniqueShielding optionsDuring TSEBT, avoid shielding the face and scalp to minimize the risk of local relapses. However, after discussing the associated risks, shared decision-making to shield face or scalp may be an option for patients who prefer to avoid hair loss in order to maintain their quality of life.Round 1Round 2Round 3446394TechniqueSpecial anatomical considerationsFor women with pendulous breasts, an irradiation bra can be used to enable sufficient dose distribution in the inframammary fold.Round 1Round 26781TechniqueAdministration of local patches or boostBased on clinical circumstances, local supplementary fields to the underdosed areas (e.g., anal folds, soles, inframammary folds) or focal radiotherapy for tumorous or residual lesions may be administered using orthovoltage, electrons, photons (e.g., IMRT, VMAT, or tomotherapy), or brachytherapy.Round 194Physics / QABeam modifiersA scatterer-degrader plate or a specialised flattening filter should be used during TSEBT to achieve the desired dose uniformity and skin dose.Round 194Physics / QATreatment distanceThe optimal treatment distance between the gantry and the patient should be assessed through measurements.Round 1100Physics / QASurface doseThe required surface dose should range from 80% to 120% of the prescribed dose.Round 1Round 26394Physics / QAIn vivo dosimetryDosimetric measurements for quality control (in vivo dosimetry) should be performed at least for a set of patients when starting the TSEBT program.Round 1100Physics / QAQuality assuranceQuality-assurance procedures, including regular equipment calibration, patient-specific dosimetric verification, and end-to-end testing or auditor certification, are recommended.Round 1100QA: quality assurance, TSEBT: total skin electron beam technique. Summary of Delphi consensus recommendations for total skin electron beam therapy. QA: quality assurance, TSEBT: total skin electron beam technique. Consensus was defined as agreement by more than 80% of respondents, and statements meeting this threshold were removed from subsequent Delphi rounds. A response rate between 66% and 80% was considered indicative of a strong level of agreement. Statements that lacked consensus were revised and re-presented in the next round. As no patient data were involved, ethical committee approval was not required. Results During the first Delphi round, consensus was reached for 7 out of 14 statements (50%). In the second round, we reached consensus on six more statements. In the third round, we agreed on the final statement. The consensus statements are listed as follows.3.1.Electrons should be used for total skin irradiation, and the electron energies must be specified based on the depth-dose characteristics. 3.1.Electrons should be used for total skin irradiation, and the electron energies must be specified based on the depth-dose characteristics. Electrons should be used for total skin irradiation, and the electron energies must be specified based on the depth-dose characteristics. No consensus was reached in the first round mainly due to disagreements regarding explicit specifications of electron beam energy ranges. In the second round, consensus was achieved that electrons should be used for total skin irradiation, and that the electron energies are selected according to depth dose characteristics (100% agreement).3.2.The daily radiation dose to each treated area should be determined according to the clinical situation, with a lifetime cumulative dose to the whole skin not exceeding 60 Gy, a local cumulative dose not exceeding 100 Gy, and the dose per fraction should be taken into account. 3.2.The daily radiation dose to each treated area should be determined according to the clinical situation, with a lifetime cumulative dose to the whole skin not exceeding 60 Gy, a local cumulative dose not exceeding 100 Gy, and the dose per fraction should be taken into account. The daily radiation dose to each treated area should be determined according to the clinical situation, with a lifetime cumulative dose to the whole skin not exceeding 60 Gy, a local cumulative dose not exceeding 100 Gy, and the dose per fraction should be taken into account. Concerning cumulative radiation dose after local or total skin irradiation, strong agreement was reached in the first round of discussions. In the second round, consensus was achieved (94% agreement) that the cumulative radiation dose following local radiation treatment and TSEBT could potentially be increased up to 100 Gy and 60 Gy (equivalent dose in 2 Gy per fraction with alpha/beta ratio of 10), respectively [1], [2], [3], [4], [5], [6]. If the response to the initial treatment course is inadequate, the panel recommends considering additional TSEBT to a higher total dose. This decision should be individualised based on factors including the duration of remission after the initial course, the dose per fraction, and the interval since the previous treatment when assessing tissue recovery [7].3.3.TSEBT requires patients to be in a standing position. 3.3.TSEBT requires patients to be in a standing position. TSEBT requires patients to be in a standing position. The standard treatment position is standing; however, in specific cases, such as for patients who have difficulty standing, alternative positions may include semi-sitting or lying down. Strong agreement on this statement was reached in the first round. In the second round, consensus was achieved with 81% agreement [19], [20], [21], [22], [23], [24], [25], [26], [27], [28]. Detailed descriptions of patient positioning and skin unfolding have been provided [17].3.4.A dual-angle technique is generally preferred, although a single-angle technique can be used. 3.4.A dual-angle technique is generally preferred, although a single-angle technique can be used. A dual-angle technique is generally preferred, although a single-angle technique can be used. Consensus was achieved in the first round, favouring the dual-angle technique as the preferred approach. A single-angle technique may be used under specific circumstances relating to the treatment room size or electron beam energy [22], [23], [24].3.5.Depending on the clinical condition of the patient and the resources of the radiotherapy facility, all fields should be applied within one scheduled fraction. Alternatively, all fields may be applied over two days. 3.5.Depending on the clinical condition of the patient and the resources of the radiotherapy facility, all fields should be applied within one scheduled fraction. Alternatively, all fields may be applied over two days. Depending on the clinical condition of the patient and the resources of the radiotherapy facility, all fields should be applied within one scheduled fraction. Alternatively, all fields may be applied over two days. Agreement to deliver a single fraction on one day increased from 75% in the first round to 88% in the second round [2], [10], [21], [29], [30]. Delivery over two days may be considered for patients who cannot stand for sufficient time to receive all fields in one day, or to accommodate the logistical restrictions within the treating facility [7].3.6.Protecting the nails and eyes is essential to avoid side effects; however, if tissues adjacent to the nails or eyelids are involved or in case of subungual disease, nails and eyelids may be irradiated with careful attention to the risk of local side effects. 3.6.Protecting the nails and eyes is essential to avoid side effects; however, if tissues adjacent to the nails or eyelids are involved or in case of subungual disease, nails and eyelids may be irradiated with careful attention to the risk of local side effects. Protecting the nails and eyes is essential to avoid side effects; however, if tissues adjacent to the nails or eyelids are involved or in case of subungual disease, nails and eyelids may be irradiated with careful attention to the risk of local side effects. To reduce radiation side effects and maintain quality of life, protection of the nails and eyes may be required. Any involved areas can still be treated, but the risk of local relapses should be assessed carefully. Ninety-four percent of the panellists agreed that protection of nails and eyes is necessary in the absence of local disease involvement. In the case of involvement, reduced doses may be administered to nails and eyelids. However, for high-dose TSEBT, it is crucial to shield the nails and eyes after administering 20 Gy.3.7.During TSEBT, avoid shielding the face and scalp to minimize the risk of local relapses. However, after discussing the associated risks, shared decision-making to shield face or scalp may be an option for patients who prefer to avoid hair loss in order to maintain their quality of life. 3.7.During TSEBT, avoid shielding the face and scalp to minimize the risk of local relapses. However, after discussing the associated risks, shared decision-making to shield face or scalp may be an option for patients who prefer to avoid hair loss in order to maintain their quality of life. During TSEBT, avoid shielding the face and scalp to minimize the risk of local relapses. However, after discussing the associated risks, shared decision-making to shield face or scalp may be an option for patients who prefer to avoid hair loss in order to maintain their quality of life. Agreement on shielding the face or scalp in the absence of head skin involvement increased from 44% in the first round to 63% in the second round, and to 94% in the third round. In the final round, the panel recommended discussing the associated risks and engaging in shared decision-making regarding shielding, allowing patients to choose this option to avoid hair loss if desired for maintaining their quality of life [31].3.8.For women with pendulous breasts, an irradiation bra can be used to enable sufficient dose distribution in the inframammary fold. 3.8.For women with pendulous breasts, an irradiation bra can be used to enable sufficient dose distribution in the inframammary fold. For women with pendulous breasts, an irradiation bra can be used to enable sufficient dose distribution in the inframammary fold. Women with pendulous breasts may benefit from a radiation bra or sling to ensure even dose distribution in the inframammary fold, reducing the need for extra local radiation. Strong agreement was reached in the first round (67%). In the second round, consensus was achieved with 81% agreement that women with pendulous breasts may benefit from the use of a radiation bra or sling to improve dose distribution in the inframammary fold [32], [33]. The use of supplementary electron fields for large lesions and patch treatments for involved skin areas receiving insufficient dose should be considered according to the individual clinical situation [17].3.9.Based on clinical circumstances, local supplementary fields to the underdosed areas (e.g., anal folds, soles, inframammary folds) or focal radiotherapy for tumorous or residual lesions may be administered using orthovoltage, electrons, photons (e.g., IMRT, VMAT, or tomotherapy), or brachytherapy. 3.9.Based on clinical circumstances, local supplementary fields to the underdosed areas (e.g., anal folds, soles, inframammary folds) or focal radiotherapy for tumorous or residual lesions may be administered using orthovoltage, electrons, photons (e.g., IMRT, VMAT, or tomotherapy), or brachytherapy. Based on clinical circumstances, local supplementary fields to the underdosed areas (e.g., anal folds, soles, inframammary folds) or focal radiotherapy for tumorous or residual lesions may be administered using orthovoltage, electrons, photons (e.g., IMRT, VMAT, or tomotherapy), or brachytherapy. Local boost or patch irradiations may be administered using orthovoltage, electrons, photons, or brachytherapy, if deemed clinically necessary. A 94% agreement on this approach was reached in the first round. The treating physician should determine the radiation dose and the timing of boosts based on clinical examinations and dosimetric measurements. The decision to deliver boost radiotherapy is made after thoroughly examining the patient following TSEBT. The panel recommends delivering boost irradiation when residual disease is suspected, particularly if deeper tumour components are unlikely to have been fully eradicated by TSEBT alone.3.10.A scatterer-degrader plate or a specialised flattening filter should be used during TSEBT to achieve the desired dose uniformity and skin dose. 3.10.A scatterer-degrader plate or a specialised flattening filter should be used during TSEBT to achieve the desired dose uniformity and skin dose. A scatterer-degrader plate or a specialised flattening filter should be used during TSEBT to achieve the desired dose uniformity and skin dose. In the first round, 94% of the panellists agreed on the need to use either a scatterer-degrader plate or a specialised flattening filter during TSEBT. The plate is introduced to improve dose uniformity by scattering the electrons and to increase the skin dose by degrading the electron beam energy. By homogenizing the treatment field, the specialised flattening filter may obviate the need for a dual-angle technique, while also potentially degrading the electron beam energy and increasing the surface dose [34].3.11.The optimal treatment distance between the gantry and the patient should be assessed through measurements. 3.11.The optimal treatment distance between the gantry and the patient should be assessed through measurements. The optimal treatment distance between the gantry and the patient should be assessed through measurements. All panellists agreed that the optimal treatment distance between the gantry and the patient should be determined based on institution-specific measurements performed within each radiation oncology department (100% agreement).3.12.The required surface dose should range from 80% to 120% of the prescribed dose. 3.12.The required surface dose should range from 80% to 120% of the prescribed dose. The required surface dose should range from 80% to 120% of the prescribed dose. During the initial discussions about surface dose and dose rate, consensus was not achieved, with only 63% agreement among panellists. In the second round, 94% of the panellists agreed that an acceptable surface dose for the lower back and umbilical region should range between 80% and 120% of the prescribed dose, and dose rate was not specified in this round. It was noted that commercial linear accelerators may provide electron beams with higher dose rates specifically designed for this technique (high dose rate electron beams).3.13.Dosimetric measurements for quality control (in vivo dosimetry) should be performed at least for a set of patients when starting the TSEBT program. 3.13.Dosimetric measurements for quality control (in vivo dosimetry) should be performed at least for a set of patients when starting the TSEBT program. Dosimetric measurements for quality control (in vivo dosimetry) should be performed at least for a set of patients when starting the TSEBT program. All panellists unanimously agreed on the usefulness of in vivo dosimetry for a selected group of patients at the start of a TSEBT program (100% agreement). Once it has been verified that the delivered dose falls within the required range, the frequency of in vivo dosimetry measurements may be reduced.3.14.Quality-assurance procedures, including regular equipment calibration, patient-specific dosimetric verification, and end-to-end testing or auditor certification, are recommended. 3.14.Quality-assurance procedures, including regular equipment calibration, patient-specific dosimetric verification, and end-to-end testing or auditor certification, are recommended. Quality-assurance procedures, including regular equipment calibration, patient-specific dosimetric verification, and end-to-end testing or auditor certification, are recommended. All panellists agreed on the importance of comprehensive quality-assurance procedures to ensure accurate and reliable radiation dose delivery (100% agreement). Occasional patient-specific dosimetric verifications can serve as helpful spot checks, and an end-to-end test can be useful in checking all the steps involved in the TSEBT workflow. Previously published guidelines from the American Association of Physicists in Medicine Task Group #30 and Medical Physics Practice Guidelines 8 provide commissioning and quality assurance recommendations [35], [36]. Discussion Skin infiltration by MF is typically highly morbid and can be challenging to treat. For these patients, TSEBT has proven efficacy and positive effects on quality of life [17], [35], [37]. To improve consistency in clinical practice and research, we provide updated guidance on the physical principles and quality-assurance requirements for the safe and reproducible delivery of TSEBT. The daily radiation dose for each treated area should be tailored to the specific clinical situation of the patient. All treatment fields can be delivered in a single scheduled session; however, depending on the patient's condition and available resources at the institution, it may be necessary to spread the radiation fraction over two days. In a literature review, twelve studies indicated that all radiation fields were treated on the same day, while ten studies employed the Stanford technique and split the treatment into two days [7]. If the initial low-dose TSEBT is insufficient, higher doses of 20 Gy or 30 Gy may be administered. This decision will depend on the patient's cumulative radiation exposure and the availability of other systemic or skin-directed treatments. The EORTC Cutaneous Lymphoma Project Group [17] recommends a cumulative TSEBT dose of 44 Gy. Based on panellists' experience, doses up to 60 Gy can be safely administered, using an equivalent dose in 2 Gy fractions (EQ.D2), with an α/β ratio of 10 Gy. Radiation oncologists need to determine the dosage and timing for re-irradiation based on each patient's individual factors. These factors include the patient's response to the initial dose, the duration of clinical benefit, and the risks associated with cumulative adverse events. In addition to these technical considerations, the panel also addressed key physics and quality assurance aspects that are essential for the safe and reproducible delivery of TSEBT. In the first round of discussions, panellists reached strong consensus on four physics-related statements. First, a scatter and attenuation plate or a special flattening filter should be used to achieve the desired dose uniformity and skin dose. Second, the optimal treatment distance between the gantry and the patient should be evaluated through precise measurements. Third, in vivo dosimetry should be performed for a selected group of patients when initiating a TSEBT program; once delivered doses are confirmed to be within the required range, the frequency of measurements may be reduced. Fourth, comprehensive quality assurance is recommended, including equipment calibration, patient-specific dosimetric verification, and end-to-end testing or auditor certification. In the second round, consensus was achieved on a fifth statement regarding surface dose, with 94% agreement that the acceptable surface dose for the lower back and umbilical region should range from 80% to 120% of the prescribed dose, although no specific dose rate was defined, allowing institutional flexibility. The current implementation of the European Medical Device Regulation (MDR) has implications for the development and use of in-house radiotherapy treatment accessories. In the context of TSEBT, locally developed solutions, such as scattering foil/flattening filter, patient rotation systems, and customised shielding devices, may be used to improve dose homogeneity, organ protection, and overall treatment quality. However, the associated regulatory burden of certification may limit innovation and availability, particularly for low-volume and highly specialised applications. In this context, the role of the Medical Physics expert is pivotal in ensuring patient safety and technical appropriateness. Proportionate regulatory pathways, including collaborative development between clinical centres and manufacturers, could strike a balance between innovation and regulatory compliance while maintaining high safety standards. These ESTRO recommendations provide a standard reference for TSEBT delivery in radiation oncology. While consensus was reached on all technical and physical aspects, individualised solutions may still be necessary depending on local resources and patient-specific circumstances. CRediT authorship contribution statement Christos Moustakis: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Isak Hannes Wahlstedt: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Investigation, Formal analysis, Data curation. Kalliopi-Pola Platoni: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Investigation, Formal analysis, Data curation. Tze Yee Lim: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Investigation, Formal analysis, Data curation. María Aurora Vicedo González: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Investigation, Formal analysis, Data curation. Trinitat García Hernández: Writing – review & editing, Writing – original draft, Visualization, Validation, Methodology, Investigation, Formal analysis, Data curation. Mario Levis: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Investigation, Formal analysis, Data curation. Gabriele Simontacchi: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Investigation, Formal analysis, Data curation. Belinda A. Campbell: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Investigation, Formal analysis, Data curation. Stefanie Corradini: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Stephen Morris: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Investigation, Formal analysis, Data curation. George Patatoukas: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Investigation, Formal analysis, Data curation. Youlia Kirova: Writing – review & editing, Writing – original draft, Visualization, Validation, Methodology, Investigation, Formal analysis, Data curation. Bouthaina Dabaja: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Investigation, Formal analysis, Data curation, Conceptualization. Hans Theodor Eich: Writing – review & editing, Writing – original draft, Validation, Methodology, Data curation. Sabbah I. Hammoury: Writing – review & editing, Writing – original draft, Validation, Supervision, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Andrea Baehr: Writing – review & editing, Writing – original draft, Validation, Supervision, Methodology, Investigation, Data curation. Livia Marrazzo: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Laila König: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Mohamed A. Schumann: Writing – review & editing, Writing – original draft, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Lena Specht: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Richard Cowan: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Khaled Elsayad: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Disclaimer ESTRO guidelines present scientific and medical opinions for educational and informational purposes only. Commercial use of any content in the guidelines without the prior written consent of ESTRO is strictly prohibited. The guidelines are not, and nor are they intended or implied to be, a substitute for professional medical advice or medical care. The advice of a medical professional should always be sought prior to commencing any form of medical treatment. Under no circumstances will ESTRO be held liable for any decision or action taken as a result of reliance on the content of the guidelines. ESTRO and all of its staff, agents and members disclaim any and all warranties and representations (implied or otherwise) with regards to the information contained on the guidelines. Each guideline is based on information available at the time the corresponding writing panel conducted its research and discussions on the topic. Guidelines should neither be deemed inclusive of all proper methods of care or factors influencing the decision making, nor exclusive of other methods reasonably directed to obtaining the same results. There may be new developments since publication that are not reflected in any one guideline and that may, over time, form the basis for ESTRO to revisit and update the guideline. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.